Maria Elisa Paiva Pires

Maria Elisa Paiva Pires

Auto-generated profile, based on publicly available information

Maria Elisa Paiva Pires

Universidade Federal do Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
TRTayla Taynan Romão
Tayla Taynan Romão
AAAbraão Iuri Medeiros Angelim
Abraão Iuri Medeiros Angelim
HPHenrique Jannuzzelli Pires Do Prado
Henrique Jannuzzelli Pires Do Prado
FGFernanda Veiga de Goes
Fernanda Veiga de Goes
MPMaria Elisa Paiva Pires
Maria Elisa Paiva Pires
IDIsabella D'ANdrea-Meira
Isabella D'ANdrea-Meira
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.

1 September 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
LNLuiz Eduardo Novis
Luiz Eduardo Novis
PFPéricles Andrade Maranhão Filho
Péricles Andrade Maranhão Filho
MPMaria Elisa Paiva Pires
Maria Elisa Paiva Pires
MSMariana Spitz
Mariana Spitz
HTHélio Afonso Ghizoni Teive
Hélio Afonso Ghizoni Teive
Faustino Monteiro Esposel was a renowned neurologist from Rio de Janeiro, born on October 24, 1888. Together with his mentor, Professor Antônio Austregésilo Rodrigues Lima - the founder of modern Brazilian Neurology -, Professor Esposel described one of the rival signs of the Babinski sign, known as the Austregésilo-Esposel sign, in a study published in the renowned journal L'Encéphale in 1912. This article aims to summarize the life story of this illustrious neurologist as well as to highlight his achievements “beyond medicine”.

1 November 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
LNLuiz Eduardo Novis
Luiz Eduardo Novis
PFPéricles Andrade Maranhão Filho
Péricles Andrade Maranhão Filho
MPMaria Elisa Paiva Pires
Maria Elisa Paiva Pires
MSMariana Spitz
Mariana Spitz
HTHélio Afonso Ghizoni Teive
Hélio Afonso Ghizoni Teive